Kiniksa Pharmaceuticals International Quarterly Cash Flow Statement
NASDAQ: KNSAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Kiniksa Pharmaceuticals International free cash flow
In the quarter ended Mar 31, 2026, Kiniksa Pharmaceuticals International generated $50.2 million of operating cash flow and spent $161,000 on capital expenditures. That left free cash flow of $50.0 million, a free-cash-flow margin of 23.4% of revenue. Free cash flow was up 125.1% from the prior year's $22.2 million.
Summary generated from market data by MetaCap's automated system. Methodology
Kiniksa Pharmaceuticals International cash flow statement (quarterly)
| Quarter (USD) | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 | Q2 20232023-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 22.59M | 14.20M | 18.43M | 17.83M | 8.54M | -8.89M | -12.69M | -3.91M | -17.70M | 25.24M | -13.86M | 14.97M |
| Net Income growth (YoY) | +164.57% | — | — | — | — | -135.22% | — | -126.10% | — | +465.73% | -106.18% | — |
| Depreciation & Amortization | 468.00K | 467.00K | 384.00K | 358.00K | 345.00K | 400.00K | 399.00K | 430.00K | 466.00K | 540.00K | 603.00K | 602.00K |
| Stock-Based Compensation | 10.06M | 10.23M | 10.14M | 8.88M | 7.75M | 8.30M | 7.83M | 7.36M | 7.21M | 7.77M | 6.79M | 6.47M |
| Change in Working Capital | 4.39M | 25.84M | -5.38M | -4.80M | -2.91M | 23.99M | 6.46M | -5.07M | 13.19M | -4.57M | 11.72M | -5.08M |
| Operating Cash Flow | 50.20M | 53.89M | 33.68M | 28.09M | 22.32M | 18.77M | -2.24M | 5.17M | 3.99M | 4.33M | 16.99M | -3.74M |
| Capital Expenditures | -161.00K | -633.00K | -671.00K | -165.00K | -99.00K | -193.00K | 0 | 0 | -84.00K | -56.00K | -16.00K | -34.00K |
| Investing Cash Flow | -31.92M | -70.81M | -62.76M | -3.88M | -51.54M | 65.29M | -6.35M | -46.80M | 25.52M | -14.89M | -12.28M | 35.53M |
| Financing Cash Flow | 6.07M | 7.66M | 11.90M | 10.70M | 2.77M | 2.14M | 6.69M | -178.00K | 3.61M | 695.00K | 552.00K | 158.00K |
| Net Change in Cash | 24.36M | -9.26M | -17.18M | 34.91M | -26.45M | 86.20M | -1.90M | -41.81M | 33.12M | -9.87M | 5.26M | 31.95M |
| Free Cash Flow | 50.04M | 53.26M | 33.01M | 27.93M | 22.23M | 18.58M | -2.24M | 5.17M | 3.90M | 4.27M | 16.97M | -3.78M |
This table shows 12 quarterly periods of Kiniksa Pharmaceuticals International's cash flow statement, from Q1 2026 back to Q2 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow KNSA's reporting calendar. What is a cash flow statement?